Subtype
Astrocytoma
CI-CAN-00004510Explore in graph →
Non-malignant74 active trials1 approved drugs24 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004510Explore in graph →
Clinical trials
362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | recruiting | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | recruiting | Phase 3 | 408 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | not yet recruiting | Phase 3 | 140 | Nuvation Bio Inc.INDUSTRY | 0 | Jul 17, 2026 | clinicaltrials |
| NCT04576117 | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | active not recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT01649830 | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma | unknown | Phase 3 | 290 | Sun Yat-sen UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT03722355 | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma | completed | Phase 3 | 712 | Radiation Therapy Oncology GroupNETWORK | 0 | Nov 12, 2019 | clinicaltrials |
| NCT01765088 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02629757 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas(β-elemene) | unknown | Phase 3 | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | completed | Phase 3 | 151 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma(SAPPHIRE) | terminated | Phase 3 | 27 | Isarna Therapeutics GmbHINDUSTRY | 16 | Nov 14, 2014 | clinicaltrials |
| NCT01656980 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | unknown | Phase 3 | 236 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 3, 2012 | clinicaltrials |
| NCT01502241 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly(Methusalem) | completed | Phase 3 | 412 | Heidelberg UniversityOTHER | 2 | Dec 30, 2011 | clinicaltrials |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | completed | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00717210 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide(NOA-04) | completed | Phase 3 | 318 | Neuro-Oncology Working Group of the German Cancer SocietyNETWORK | 1 | Jul 17, 2008 | clinicaltrials |
| NCT00430911 | Radiotherapy for Malignant Astrocytomas in the Elderly | completed | Phase 3 | — | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 2, 2007 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials